Core Viewpoint - The company has reported a decline in domestic revenue due to market challenges while achieving growth in overseas markets, driven by strategic innovations and product development [5][6][9]. Group 1: Company Overview - The company focuses on independent innovation and continuous technological advancements to provide high-quality in vitro diagnostic products globally [5]. - The company has not changed its controlling shareholder or actual controller during the reporting period [5]. Group 2: Financial Performance - The company achieved operating revenue of 1.84 billion yuan, a decrease of 1.18% year-on-year, with a total profit of 875 million yuan, down 15.87% year-on-year [9]. - The net profit attributable to shareholders was 771 million yuan, a decrease of 14.62% compared to the previous year [9]. Group 3: Domestic Market Performance - Domestic revenue from in vitro diagnostic services was 1.23 billion yuan, a year-on-year decline of 12.81%, with reagent revenue down 18.96% and instrument revenue up 18.18% [6]. - The company installed 774 units of chemiluminescence immunoassay analyzers, with a 74.81% share of large machines, and served 1,835 tertiary hospitals, achieving a coverage rate of 47.60% [6]. Group 4: International Market Performance - The company established a wholly-owned subsidiary in South Korea and has built operational systems in 14 core countries, enhancing its global brand influence [7]. - Overseas revenue reached 952 million yuan, a year-on-year increase of 19.57%, with reagent business growing by 36.86% [7]. Group 5: Product Development and Sales - The flagship model MAGLUMI X8 has achieved a cumulative installation of 4,300 units, reinforcing the company's leading position in high-end chemiluminescence [8]. - The company has successfully launched the SATLARS T8 automated laboratory line, with a total of 179 lines installed globally [8]. Group 6: Profitability Metrics - The overall gross margin was 68.64%, with instrument gross margin at 26.16%, reflecting a strategic differentiation in product offerings [9].

报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 2025年3月24日，为期三天的 第二十二届中国国际检验医学暨输血仪器试剂博览会（CACLP） 在杭州大会展中心正式落下帷幕。 此次大会，迈瑞医疗发布了 MT 8000S独立式智能样本处理系统 ，覆盖从样本签收到上机检测前的所有处理环节，通过数字视觉和模型算法，确保整个样本处理 过程处于IT+AI控制之下。另外，迈瑞还发布了 全新一代H-120全自动糖化血红蛋白分析仪、CX—9000高端凝血分析仪和MN 2880全自动核酸提纯及实时荧光 PCR分析系统 （分子诊断领域的重要产品，定义核酸检测新常规）。 作为全球体外诊断（IVD）行业极具影响力的盛会之一，本届展会以" 以创新的力量，助力IVD产业健康发展 "为主题，全方位展示了体外诊断领域的最新技术和产 品。随着人工智能、大数据、物联网等技术的迅猛发展，智能化诊断成为本届展会的最大亮点。 此次大会， 丹纳赫、罗氏、雅培、豪洛捷等 国际巨头携最新研发成果强势登场，全方位覆盖仪器、试剂、原材料等关键展区。从前 ...